Arix Bioscience Plc Director/PDMR Shareholding (1896B)

TIDMARIX

RNS Number : 1896B

Arix Bioscience Plc

31 May 2023

Arix Bioscience plc

(the "Company")

PDMR notification & Director Shareholding

The Company today announces it has granted an executive award of nil cost options (the "Award") under the Arix Bioscience plc Executive Incentive Plan (the "Plan") to CEO Robert Lyne, which are subject to performance conditions over a three-year period from 1 January 2023 to 31 December 2025 (the "Performance Period"). The Award takes the form of an option to acquire up to 671,800 ordinary shares of GBP0.00001 each in the Company. Vested Shares are subject to a further two-year holding period, as set out in the Plan. The performance conditions attached to the Award are set out in the Director's Remuneration Report on page 55 of Company's Annual Report & Accounts 2022.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                       Robert Lyne 
      -----------------------------------------  ---------------------------------------------------------- 
       Reason for the notification 
  2 
      ----------------------------------------------------------------------------------------------------- 
 a)    Position/status                            Chief Executive Officer 
      -----------------------------------------  ---------------------------------------------------------- 
 b)    Initial notification                       Initial Notification 
        /Amendment 
      -----------------------------------------  ---------------------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------------------------------- 
 a)    Name                                       Arix Bioscience plc 
      -----------------------------------------  ---------------------------------------------------------- 
 b)    LEI                                        213800OVT3AHQCXNIX43 
      -----------------------------------------  ---------------------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions have been conducted 
      ----------------------------------------------------------------------------------------------------- 
 a)    Description of the                         Arix Bioscience plc Ordinary shares of 0.001 
        financial instrument,                      pence each 
        type of instrument 
       Identification code                        GB00BD045071 
 b)    Nature of the transaction                  Award of nil-cost options under the Arix Bioscience 
                                                   plc Executive Incentive Plan ("EIP") 
----  -----------------------------------------  ---------------------------------------------------------- 
c)     Price(s) and volume(s)                      Price(s)                    Volume(s) 
      -----------------------------------------   --------------------------  --------------------------- 
    Nil                                                                        671,800 
   -------------------------------------------------------------------------  --------------------------- 
 d)    Aggregated information 
  - Aggregated volume                        N/A (Single Transaction) 
  - Price                                    N/A (Single Transaction) 
 e)    Date of the transaction                    30 May 2023 
 f)    Place of the transaction                   Outside a trading venue 
      -----------------------------------------  ---------------------------------------------------------- 
 

For further information please contact:

Kin Company Secretarial Limited, Company Secretary

[phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBFLFXXELEBBB

(END) Dow Jones Newswires

May 31, 2023 06:51 ET (10:51 GMT)